Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: The life study
Open Access
- 17 March 2004
- journal article
- clinical trial
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 43 (6), 1047-1055
- https://doi.org/10.1016/j.jacc.2003.11.029
Abstract
Objectives: We report on a subanalysis of the effects of losartan and atenolol on cardiovascular events in black patients in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Background: The LIFE study compared losartan-based to atenolol-based therapy in 9,193 hypertensive patients with left ventricular hypertrophy (LVH). Overall, the risk of the primary composite end point (cardiovascular death, stroke, myocardial infarction) was reduced by 13% (p = 0.021) with losartan, with similar blood pressure (BP) reduction in both treatment groups. There was a suggestion of interaction between ethnic background and treatment (p = 0.057). Methods: Exploratory analyses were performed that placed LIFE study patients into black (n = 533) and non-black (n = 8,660) categories, overall, and in the U.S. (African American [n = 523]; non-black [n = 1,184]). Results: A significant interaction existed between the dichotomized groups (black/non-black) and treatment (p = 0.005); a test for qualitative interaction was also significant (p = 0.016). The hazard ratio (losartan relative to atenolol) for the primary end point favored atenolol in black patients (1.666 [95% confidence interval (CI) 1.043 to 2.661]; p = 0.033) and favored losartan in non-blacks (0.829 [95% CI 0.733 to 0.938]; p = 0.003). In black patients, BP reduction was similar in both groups, and regression of electrocardiographic-LVH was greater with losartan. Conclusions: Results of the subanalysis are sufficient to generate the hypothesis that black patients with hypertension and LVH might not respond as favorably to losartan-based treatment as non-black patients with respect to cardiovascular outcomes, and do not support a recommendation for losartan as a first-line treatment for this purpose. The subanalysis is limited by the relatively small number of events.Keywords
This publication has 19 references indexed in Scilit:
- Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA, 2002
- Effect of Blood Pressure Lowering and Antihypertensive Drug Class on Progression of Hypertensive Kidney DiseaseResults From the AASK TrialJAMA, 2002
- Effects of Losartan on Cardiovascular Morbidity and Mortality in Patients With Isolated Systolic Hypertension and Left Ventricular HypertrophyJAMA, 2002
- The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 DiabetesNew England Journal of Medicine, 2001
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001
- Effect of Ramipril vs Amlodipine on Renal Outcomes in Hypertensive NephrosclerosisA Randomized Controlled TrialJAMA, 2001
- A Trial of the Beta-Blocker Bucindolol in Patients with Advanced Chronic Heart FailureNew England Journal of Medicine, 2001
- Racial differences in response to therapy for heart failure: Analysis of the vasodilator-heart failure trialsJournal of Cardiac Failure, 1999
- Characteristics of 9194 Patients With Left Ventricular HypertrophyHypertension, 1998
- Effect of Single-Drug Therapy on Reduction of Left Ventricular Mass in Mild to Moderate HypertensionCirculation, 1997